LTA4H INHIBITORS FOR TREATING PURULENT HYDRADENITIS Russian patent published in 2024 - IPC A61K31/4439 A61K45/06 A61P17/02 A61P17/10 A61P17/00 C07D401/12 

FIELD: chemistry.

SUBSTANCE: invention relates to methods of treating purulent hydradenitis, specifically to the use of an LTA4H inhibitor for treating or preventing purulent hydradenitis in a patient in need of such treatment. Said LTA4H inhibitor is (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2 H-tetrazol-2-yl)butanoic acid or a pharmaceutically acceptable salt thereof; or said LTA4H inhibitor is a crystalline form (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, where said crystalline form is characterized by a powder X-ray diffraction pattern containing characteristic peaks at 2θ at 22.6 ± 0.2 °2θ, 24.1 ± 0.2 °2θ and 26.3 ± 0.2 °2θ measured at temperature of approximately 25 °C, and at x-ray wavelength λ of 1.5418 Å. Invention also relates to use of a pharmaceutical composition based on said compound or its crystalline form.

EFFECT: treatment with said compound or its crystalline form of purulent hydradenitis.

10 cl, 17 dwg, 2 tbl, 8 ex